EMPOWERING PEOPLE AFFECTED BY TB THROUGH DIGITAL ADHERENCE TECHNOLOGY

The Unitaid supported ASCENT project aims to help people affected by TB succeed in their TB treatment using digital adherence technology

Tuberculosis (TB) is still the deadliest infectious disease worldwide, killing over 4.000 people every day. This is unnecessary as TB can be cured with appropriate treatment. A number of barriers however, prevent people from recovering from this disease, including long and complicated treatment regimens that involve the daily intake of medicines over the course of 6-24 months.

By leveraging today’s smart information and (mobile) communication technologies the ASCENT project (Adherence Support Coalition to End TB) aims to support people affected by TB with their treatment in a modern and more effective way through the use of digital adherence technologies such as smart pill boxes, medication sleeves and video supported treatment.

By generating evidence, establishing a global market and engaging stakeholders, ASCENT aims to make future scale up possible so that these digital innovations can be available to all people living with TB worldwide.

What next?

The ASCENT project extension (ASCENT DR-TB) through 2025 aims to supporting countries to create the conditions for successful accelerated scale-up of the use of the latest and shorter TB treatment regimens.  It will do so by creating conditions for accelerating the adoption of safer and more effective treatments for Rifampicin Resistant/Multidrug Resistant TB (RR/MDR-TB) in 8 countries.

news & Stories

Funding & support

Consortium partners

Funding & Support

Consortium partners

more about the ascent project